Research Insights

Discover key insights and interpretations of recent research papers and clinical trials for undefined.

Improvement in fecal calprotectin, a key marker of intestinal inflammation, was observed in 82% of patients, showcasing upadacitinib's effectiveness in reducing gut inflammation.

Induction with upadacitinib in Crohn’s disease: real-world experience from an early-access program in Greece

Annals of Gastroenterology - 1/1/2025

MECHANISM

5/18/2025

Target

Fecal calprotectin levels

Crohn's Disease

Adverse events were mild and occurred in 14% of participants, with no severe complications, underscoring upadacitinib's safety in Crohn's Disease treatment.

Induction with upadacitinib in Crohn’s disease: real-world experience from an early-access program in Greece

Annals of Gastroenterology - 1/1/2025

TREATMENT

5/18/2025

Target

Adverse events (safety profile)

Crohn's Disease

Upadacitinib allowed discontinuation of corticosteroids in 100% of the cohort after 12 weeks of treatment.

Induction with upadacitinib in Crohn’s disease: real-world experience from an early-access program in Greece

Annals of Gastroenterology - 1/1/2025

TREATMENT

5/18/2025

Target

Steroid-sparing therapy

Crohn's Disease

Normalization of C-reactive protein (CRP) was achieved in 85% of patients by week 8, demonstrating effective control of inflammation by upadacitinib.

Induction with upadacitinib in Crohn’s disease: real-world experience from an early-access program in Greece

Annals of Gastroenterology - 1/1/2025

TREATMENT

5/18/2025

Target

Inflammation markers (C-reactive protein)

Crohn's Disease

Upadacitinib, a Janus kinase-1 inhibitor, achieved an 85% clinical response rate over 12 weeks in a cohort of Crohn's Disease patients refractory to three or more biologic treatments.

Induction with upadacitinib in Crohn’s disease: real-world experience from an early-access program in Greece

Annals of Gastroenterology - 1/1/2025

TREATMENT

5/18/2025

Target

Janus kinase-1 pathway

Crohn's Disease

Rectal bleeding is more prevalent among Black (2.85%), Hispanic (2.51%), and Asian (2.21%) Crohn's Disease patients than Whites (1.79%), with Black patients showing an aOR of 1.42.

Racial disparity in inflammatory bowel disease-related complications: a nationwide cohort study

Annals of Gastroenterology - 1/1/2025

OTHER

5/18/2025

Target

rectal bleeding

Crohn's Disease

Asian patients with Crohn's Disease show the highest rate of intestinal obstruction (11.8%), compared to 8.32% in Whites. The aOR for Asian patients is 1.09.

Racial disparity in inflammatory bowel disease-related complications: a nationwide cohort study

Annals of Gastroenterology - 1/1/2025

OTHER

5/18/2025

Target

intestinal obstruction

Crohn's Disease

Black patients with Crohn's Disease (CD) exhibit a 2.88% anal abscess rate, significantly higher than the White population (1.25%), with adjusted odds ratio (aOR) of 1.41.

Racial disparity in inflammatory bowel disease-related complications: a nationwide cohort study

Annals of Gastroenterology - 1/1/2025

OTHER

5/18/2025

Target

anal abscess

Crohn's Disease

Decreased plasma ACE2 levels in Crohn's Disease do not imply increased susceptibility to SARS-CoV-2, differing from initial concerns.

Altered plasma levels of the SARS-CoV-2-related proteins ACE2 and TMPRSS2 in patients with Crohn’s disease

Scientific Reports - 12/5/2024

OTHER

5/9/2025

Target

SARS-CoV-2 susceptibility

Crohn's Disease

Plasma levels of TMPRSS2 prodomain fragment decrease in Crohn's Disease patients before treatment, but recover partially with azathioprine or ustekinumab.

Altered plasma levels of the SARS-CoV-2-related proteins ACE2 and TMPRSS2 in patients with Crohn’s disease

Scientific Reports - 12/5/2024

MECHANISM

5/9/2025

Target

TMPRSS2 protein levels

Crohn's Disease